FDA approves Zelboraf for Erdheim-Chester Disease6 Nov 2017
Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease ECD, a rare blood disease.
Genentech, a member of the Roche Group, has announced that the FDA has approved Zelboraf (vemurafenib) for Erdheim-Chester disease (ECD) with BRAF V600 mutation. ECD is a rare, serious blood disease characterized by the abnormal multiplication of certain white blood cells called histiocytes, which can invade normal tissues and organs in the body.
The approval is based on data from the Phase II VE-BASKET study. Basket studies use an innovative clinical trial design that helps collect data faster and may accelerate the development of medicines for diseases with high unmet need. Instead of enrolling people based primarily on their disease or its location, basket studies match a disease’s underlying genetic profile to the mechanism of action of the medicine.
“This FDA decision means people living with Erdheim-Chester disease will now, for the first time, have an FDA-approved treatment option,” said Sandra Horning, chief medical officer and head of Global Product Development. “We are committed to finding new ways to bring medicines to patients with high unmet need, and we are pleased that this innovative clinical trial helped identify Zelboraf for treatment of this rare disease.”
“The Erdheim-Chester disease community is very encouraged by this first FDA-approved treatment for ECD, bringing new hope to patients and their families,” said Kathleen Brewer, president of ECD Global Alliance. “This new treatment option shows that meaningful breakthroughs can occur rapidly when patients, families, research physicians, industry and the FDA work together to help patients.”
Final results of VE-BASKET for the 22 people with ECD showed a best overall response rate of 54.5%. The most common Grade 3 or higher adverse events were new skin cancers, high blood pressure, rash and joint pain. The most common adverse events were joint pain, rash, hair loss, fatigue, change in heart rhythm and skin tags.
Zelboraf monotherapy was approved for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation in 2011. The FDA previously granted Priority Review and Breakthrough Therapy Designation to Zelboraf for ECD with BRAF V600 mutation.
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Concept Life Sciences extends GLP accreditation to support regulatory studies
10 Nov 2018
Accreditation ensures quality and integrity of non-clinical laboratory studies to support pharmaceutical and biotech industries.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
Sandoz pulls the plug on US biosimilar rituximab
4 Nov 2018
Company will focus on robust biosimilar portfolio for unmet access and sustainability needs.Read more
Symbiosis secures FDA viral vector process approval
5 Oct 2018
Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.Read more
New oral treatment for metastatic melanoma receives EU authorisation
24 Sep 2018
Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).Read more
NMPA approves fruquintinib capsules for metastatic colorectal cancer
13 Sep 2018
Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.Read more
The 6-month FMD countdown - are you ready?
21 Aug 2018
With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?Read more
Protecting the links between the UK and the EMA
14 Aug 2018
Now less than a year away from when the UK officially leaves the EU, the main goal remains the same - maintaining access to new drugs for patient health.Read more
TraceLink announces Russia compliance solution
13 Aug 2018
Company helps customers navigate and company with "one of the most complicated track and trace regulations in the world".Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation